SCHEMBL15845911

SCHEMBL15845911

Cc1cc(C(=O)N2CCCCC2)sc1-c1cc(OCOCC[Si](C)(C)C)c2ncn(COCC[Si](C)(C)C)c(=O)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.36
▸ BRD9 Q9H8M2 1/20 0.36
▸ TSHR P16473 2/20 0.35
▸ NPSR1 Q6W5P4 4/20 0.33
▸ NPC1 O15118 4/20 0.33
▸ RAB9A P51151 4/20 0.33
▸ ATM Q13315 1/20 0.33
▸ HPGD P15428 5/20 0.32
▸ ALDH1A1 P00352 4/20 0.32
▸ SMN1; SMN2 Q16637 3/20 0.32
▸ POLB P06746 2/20 0.32
▸ LMNA P02545 2/20 0.32
▸ PPARD Q03181 2/20 0.32
▸ PPARA Q07869 2/20 0.32
▸ USP2 O75604 1/20 0.32
▸ CREBBP Q92793 1/20 0.32
▸ PPARG P37231 1/20 0.32
▸ HTT P42858 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15846482 0.93 TSHR (0.36) BRD4BRD9TSHRNPSR1ATM
SCHEMBL15845887 0.87 DGAT1 (0.34) EGFRIGF1RSRCFLT4KDR
SCHEMBL17391750 0.76 F2RL3 (0.34) BRD4CREBBPEGFRIGF1RSRC
SCHEMBL15846275 0.76 F2RL3 (0.34) EGFRIGF1RSRCFLT4KDR
SCHEMBL15845841 0.75 NPC1 (0.38) NPC1EGFRIGF1RSRCFLT4
SCHEMBL15846300 0.75 CD38 (0.34) BRD4CREBBPEGFRIGF1RSRC
SCHEMBL15859651 0.75 F2RL3 (0.38) NPSR1NPC1ATMLMNAEGFR
SCHEMBL15859688 0.74 EGFR (0.39) BRD4NPSR1NPC1RAB9AHPGD
SCHEMBL15845858 0.74 EGFR (0.35) BRD4NPC1HPGDALDH1A1SMN1; SMN2
SCHEMBL17391748 0.74 NPC1 (0.33) NPSR1NPC1RAB9AHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 — — US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 — — EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 — — EP disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 BRD4 3433/4885BRD9 4504/4885TSHR 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback